ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0296

Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals

Carolina Munoz-grajales1, Stephenie Prokopec2, Dennisse Bonilla3, Earl D. Silverman4, Sindhu Johnson3, Arthur Bookman5, Zahi Touma6, Zareen Ahmad7, Linda Hiraki8, Paul Boutros9, Andrzej Chruscinski10 and Joan Wither3, 1University of Toronto, Toronto, Canada, 2Ontario Institute for Cancer Research, Toronto, Canada, 3University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, 4Division of Rheumatology, The Hospital for Sick Children, Translational Medicine, Research Institute, The Hospital for Sick Children, and Department of Paediatrics, University of Toronto., Toronto, ON, Canada, 5Division of Rheumatology, University Health Network; 8Department of Medicine, University of Toronto; Division of Rheumatology, Toronto, Canada, 6University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network; Krembil Research Institute, Toronto, ON, Canada, 7Department of Medicine, University of Toronto; Division of Rheumatology, Mount Sinai Hospital, Toronto, Canada, 8Division of Rheumatology, The Hospital for Sick Children; Department of Medicine, University of Toronto, Toronto, Canada, 9Department of Immunology, University of Toronto; Department of Medical Biophysics, University of Toronto; Department of Pharmacology and Toxicology, University of Toronto; Department of Human Genetics, University of California; Department of Urology, University of California; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California; Institute for Precision Health, University of California; Jonsson Comprehensive Cancer Centre, University of California, Toronto, Canada, 10Multi-Organ Transplant Program, University Health Network, Toronto, Canada

Meeting: ACR Convergence 2020

Keywords: Autoantibody(ies), autoantigens, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Etiology & Pathogenesis Poster

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Within the Anti-Nuclear Antibody (ANA) associated Systemic Autoimmune Rheumatic Diseases (SARD), such as Systemic Lupus Erythematous (SLE), Sjögren’s Syndrome (SS), and Systemic Sclerosis (SSc), changes in the quantity and/or abundance of specific auto-antibodies (auto-Ab) occur as individuals progress towards SARD. However, previous studies have examined only a small number of ANAs. Thus, additional changes in the auto-Ab profile may accompany and predict disease progression that have not yet been appreciated. To address this, we examined the auto-Ab profile for a broad range of auto-antigens (auto-Ag) across 245 ANA+ asymptomatic and symptomatic individuals.

Methods: A microarray was used to simultaneously measure 144 auto-Ab specificities across six patient groups: ANA– healthy controls (HC, n=38); ANA+ (≥1:160 by IF) individuals lacking SARD criteria (ANA+ NS, n=83); individuals with ≥ 1 SARD criteria but with insufficient evidence for a diagnosis (undifferentiated connective tissue disease; UCTD, n=52); early untreated (except anti-malarial) SARD patients (n=26 SLE, n=30 SS, and n=16 SSc, classified according to the 1997 ACR criteria, 2013 ACR-EULAR criteria, and the 2016 ACR-EULAR criteria, respectively). ANA+ NS and UCTD patients were followed yearly for up to 4 years, 12 of which demonstrated symptom progression. Eleven specific ANAs were detected using the Bioplex 2200 ANA-Screen and the expression levels of five IFN-α induced genes were measured and summed to generate an IFN5 score.

Results: Following unsupervised hierarchical clustering, IgG but not IgM auto-Ab showed clear patterns by diagnosis (heat map for IgG shown in Figure 1). A subset of ANA+ NS and UCTD individuals were admixed with SLE and SS patients, which included the majority of progressors. In general, there was a moderate positive correlation between the levels of the auto-Ab detected by Bioplex and the corresponding auto-Ab in the microarray, however, using 2 standard deviations above the mean for ANA– HC as a cut-off, elevated levels of auto-Ab were seen more frequently in ANA+ individuals by microarray than by Bioplex. Furthermore, the microarray was able to detect differences in auto-Ab levels above the upper limit of detection on Bioplex, with very high levels restricted to SARD patients (Figure 2). Many more auto-Ag were recognized by IgG auto-Ab in SLE than in the other ANA+ groups indicating that self-tolerance is significantly more disrupted in SLE (Figure 3). Interestingly, although anti-Ro60 had the strongest correlation with IFN-induced gene expression, only the presence of IgG anti-Ro52 at baseline was associated with progression in ANA+ individuals lacking a SARD diagnosis. Strikingly, the types and levels of auto-Abs remained remarkably stable over time in these individuals regardless of whether they progressed or not.

Conclusion: ANA+ individuals have auto-Ab to many self-antigens that are not being captured by current screening techniques. Measurement of these additional auto-Ab specificities, together with the larger dynamic range of the microarray, may help to identify individuals at high risk of progression.

Figure 1. Heat Map of selected antigens following unsupervised clustering. IgG auto-Ab levels in red are high and those in blue are low. Controls are clustered on the left. Note the admixture of asymptomatic ANA+ and UCTD individuals with the early SARD patients, indicating similar auto-Ab profiles. Figure 2. Representative plot showing the levels of auto-Ab (Sm antigen and SmD3 subcomponent in this example) determined by microarray. Note that very high levels are restricted to SLE patients. Figure 3. P-value sensitivity plot examining the number of significantly differentially abundant probes relative to healthy controls, where it can be appreciated that many more IgG auto-Abs are elevated in SLE than in the other ANA+ groups.


Disclosure: C. Munoz-grajales, None; S. Prokopec, None; D. Bonilla, None; E. Silverman, None; S. Johnson, None; A. Bookman, None; Z. Touma, None; Z. Ahmad, None; L. Hiraki, None; P. Boutros, None; A. Chruscinski, None; J. Wither, None.

To cite this abstract in AMA style:

Munoz-grajales C, Prokopec S, Bonilla D, Silverman E, Johnson S, Bookman A, Touma Z, Ahmad Z, Hiraki L, Boutros P, Chruscinski A, Wither J. Investigating the Differences in ANA Specificities Between Asymptomatic and Symptomatic ANA+ Individuals [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/investigating-the-differences-in-ana-specificities-between-asymptomatic-and-symptomatic-ana-individuals/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/investigating-the-differences-in-ana-specificities-between-asymptomatic-and-symptomatic-ana-individuals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology